Search

everythinglearnresearchcommunity

for

Search:↓

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.

A Holstein calf in Iran with a severe genetic skin disorder was euthanized due to incurable symptoms.

P2X₃-IR fibers are widespread in rat skin and likely help detect pain.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

IL-15 promotes hair growth and protects hair follicles.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Targeting mitophagy may help treat alopecia areata by reducing inflammasome activation.

Blood cells turned into stem cells can become skin cells similar to normal ones, potentially helping in skin therapies.

Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.

Overexpressing PKCα in mice skin increases inflammation but doesn't affect tumor growth.

IRS-specific genes in Tan sheep hair follicles peak at birth and may affect wool crimp.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Keratin 10 end domains may increase skin cancer risk by reducing cell death.

UTX is crucial for skin differentiation and health, especially in females.

Baricitinib significantly regrows hair in severe alopecia areata patients.

The protein RSL4 is crucial for making root hairs longer by controlling genes related to cell growth.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

OCT4B1 and SOX-2 levels are higher in Crohn's and ulcerative colitis patients, possibly aiding tissue repair.

Certain genetic variants in ERN1, TACR3, and SPPL2C are linked to when Alzheimer's disease starts.

Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.